HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it intends to offer to sell, subject to market and other conditions, 3,376,960 shares of its common stock in an underwritten public offering. In addition to the shares being offered by the Company, 123,040 shares will be offered by certain affiliate stockholders. Acorda Therapeutics will grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock at the public offering price. The final terms of the offering will be disclosed in the final prospectus to be filed with the Securities and Exchange Commission.
